69 completed, 16 terminated, 13 active not recruiting, 12 recruiting. 136 Phase 2, 41 Phase 1, 5 Phase 3.
Follow Bendamustine: new trials by email Literature Review of Bendamustine trials Research Report on Bendamustine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Trial of MK-1045 With Zilovertamab Vedotin in Participants With Diffuse Large B-cell Lymphoma (MK-1045-010) MK-1045, Zilovertamab vedotin, Rituximab - Lymphoma, Large B-Cell, Diffuse, Diffuse Large B-Cell Lymphoma | Phase 2 / Phase 3 | Not yet recruiting | Merck Sharp & Dohme LLC | 470 | 2026-12-13 | 2026-11-05 |
| A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007) MK-1045, Rituximab, Rituximab biosimilar - Follicular Lymphoma | Phase 2 / Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 960 | 2026-06-22 | 2026-11-13 |
| Pralatrexate With Bendamustine and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma Bendamustine, Pralatrexate, Bone Marrow Aspiration - Recurrent T-Cell Non-Hodgkin Lymphoma, Refractory T-Cell Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 50 | 2026-04-27 | 2026-05-11 |
| Treatment of Participants With Primary or Secondary Progressive Multiple Sclerosis TRX319, Bendamustine - Primary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis (SPMS) | Phase 1 / Phase 2 | Recruiting | Tr1X, Inc. | 39 | 2026-03-01 | 2026-09-21 |
| A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma Rocbrutinib, Bendamustine, Rituximab - Diffuse Large B-Cell Lymphoma (DLBCL) | Phase 2 | Recruiting | Guangzhou Lupeng Pharmaceutical Company LTD. | 150 | 2025-11-27 | 2025-12-16 |
| Phase II Trial of Zanubrutinib, Obinutuzumab, Bendamustine (ZGB) as First-Line Therapy for Chronic Lymphocytic Leukemia: A Single-Center Study Zanubrutinib, Obinutuzumab, Bendamustine - Chronic Lymphocytic Leukemia | Phase 2 | Not yet recruiting | The First Hospital of Jilin University | 30 | 2025-06-15 | 2025-06-04 |
| MRD Guided De-intensification of Bendamustine/Rituximab for Indolent Non-Hodgkin Lymphoma Bendamustine, Rituximab - Lymphoma, Indolent Non-hodgkin Lymphoma | Phase 2 | Not yet recruiting | Fox Chase Cancer Center | 24 | 2025-06-01 | 2025-01-06 |
| Obinutuzumab With CHOP Versus Obinutuzumab With Bendamustine in the Treatment of Newly Diagnosed Follicular Lymphoma Grade 3A Obinutuzumab, CHOP, Bendamustine - Follicular Lymphoma Grade 3A | Phase 2 | Not yet recruiting | Sun Yat-sen University | 133 | 2025-05-01 | 2025-05-08 |
| BRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Naïve Mantle Cell Lymphoma Bendamustine, Rituximab, Cytarabine - Mantle Cell Lymphoma, Lymphoma | Phase 2 | Recruiting | Christine Ryan | 60 | 2025-04-22 | 2026-02-20 |
| Efficacy and Safety of Zuberitamab Combined with Bendamustine, Followed by Monotherapy Maintenance, in Treatment-naïve Follicular Lymphoma Zuberitamab, Bendamustine - Follicular Lymphoma (FL) | Phase 2 | Not yet recruiting | Sun Yat-sen University | 50 | 2025-02-01 | 2025-01-03 |
| Zanubrutinib, Bendamustine, Rituximab Prev. Untreated WM Zanubrutinib, Bendamustine, Rituximab - Waldenstrom Macroglobulinemia | Phase 2 | Recruiting | Massachusetts General Hospital | 65 | 2024-12-20 | 2026-11-13 |
| A Study of Zanubrutinib in Combination With Polatuzumab Vedotin, Bendamustine and Rituximab in the Treatment of Relapsed/Refractory Diffuse Large B-cell Lymphoma Zanubrutinib, Polatuzumab Vedotin, Bendamustine - Refractory or Relapsed Diffuse Large B Cell Lymphoma | Phase 2 | Recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 36 | 2024-08-31 | 2024-08-15 |
| A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma Golcadomide, Rituximab, Cyclophosphamide - Lymphoma, Follicular | Phase 2 | Active not recruiting | Celgene | 95 | 2024-08-30 | 2026-07-31 |
| Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy Epcoritamab, Lenalidomide, Rituximab - Relapsed Follicular Lymphoma, Refractory Follicular Lymphoma | Phase 2 | Recruiting | University of Birmingham | 284 | 2023-09-04 | 2026-05-05 |
| A Phase 2 Clinical Trial to Evaluate Zanubrutinib Combined With BR (Bendamustine/Rituximab) Regimen in Subjects With Newly-diagnosed Waldenström's Macroglobulinemia Zanubrutinib, Bendamustine, Rituximab - Waldenström's Macroglobulinemia | Phase 2 | Unknown | Shanghai Changzheng Hospital | 60 | 2023-08-01 | 2023-09-14 |
| Study of Atezolizumab Plus BEGEV Regimen in Relapsed or Refractory Hodgkin's Lymphoma Patients Atezolizumab, BEGEV - Relapsed or Refractory Hodgkin's Lymphoma | Phase 1 / Phase 2 | Active not recruiting | Fondazione Italiana Linfomi - ETS | 122 | 2023-02-27 | 2026-09-11 |
| A Study of Tazemetostat With Rituximab and Abbreviated Bendamustine in the Frontline Treatment of High Tumor Burden Follicular Lymphoma Bendamustine, Rituximab, Tazemetostat - Follicular Lymphoma | Phase 1 / Phase 2 | Active not recruiting | Vaishalee Kenkre | 42 | 2023-01-26 | 2026-02-17 |
| Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis Venetoclax Oral Tablet, 200 mg, FISH assay, Venetoclax Oral Tablet, 400 mg - AL Amyloidosis | Phase 1 / Phase 2 | Active not recruiting | Columbia University | 53 | 2022-10-26 | 2026-10-08 |
| A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (MK-4280A-008) favezelimab/pembrolizumab, bendamustine, gemcitabine - Hodgkin Lymphoma | Phase 2 | Completed | Merck Sharp & Dohme LLC | 203 | 2022-10-18 | 2026-09-01 |
| Autologous Hematopoietic Stem Cell Transplantation in Pediatric Relapsed or Refractory Hodgkin Lymphoma After Nivolumab Treatment Nivolumab - Relapsed or Refractory Hodgkin Lymphoma, Children | Phase 2 | Enrolling by invitation | St. Petersburg State Pavlov Medical University | 20 | 2022-06-01 | 2025-04-17 |
Showing 20 of 136. Sign in to see all of them.
Lymphoma (27) · Leukemia, Lymphocytic, Chronic, B-Cell (23) · Lymphoma, Non-Hodgkin (22) · Hodgkin Disease (18) · Lymphoma, Large B-Cell, Diffuse (18) · Multiple Myeloma (17) · Lymphoma, Follicular (16) · Lymphoma, Mantle-Cell (16) · Recurrence (16) · Leukemia (7) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (6) · Leukemia, B-Cell (4) · Lymphoma, B-Cell (4) · Lymphoma, B-Cell, Marginal Zone (4) · Waldenstrom Macroglobulinemia (4)
M.D. Anderson Cancer Center (8) · German CLL Study Group (7) · Hoffmann-La Roche (4) · Merck Sharp & Dohme LLC (4) · Celgene (3) · Columbia University (3) · Fondazione Italiana Linfomi - ETS (3) · SCRI Development Innovations, LLC (3) · Seagen Inc. (3) · Sun Yat-sen University (3) · University of Wisconsin, Madison (3) · Arbeitsgemeinschaft medikamentoese Tumortherapie (2) · Cephalon (2) · Christine Ryan (2) · Emory University (2)
United States (85) · Germany (21) · Italy (20) · France (17) · Canada (15) · Poland (12) · Spain (12) · United Kingdom (12) · China (10) · Australia (9) · South Korea (9) · Israel (7) · Belgium (6) · Czechia (5) · Russia (5)
Paula Cramer, Dr. med. (4) · Julie Chang, MD (3) · Armando Santoro, MD (2) · Christine Ryan, MD (2) · Issa F Khouri (2) · Richard Greil, Prof.Dr. (2) · Agostino Cortelezzi, Pr. (1) · Ajay Gopal (1) · Amitabha Mazumder, MD (1) · Andrew Branagan, MD, PhD (1)
PMID 38620092, PMID 34086865, PMID 19860608, PMID 21239695, PMID 21844497, PMID 22869884, PMID 23109692, PMID 23430121, PMID 23753028, PMID 23955074, PMID 24359243, PMID 24925211, PMID 25911554, PMID 26331432, PMID 26377597, PMID 26729345, PMID 26913697, PMID 27222473, PMID 27382096, PMID 27442600, PMID 29038340, PMID 29226797, PMID 29276022, PMID 29703778, PMID 30518502, PMID 30568174, PMID 31073022, PMID 31190006, PMID 31693429, PMID 31935284, PMID 32083996, PMID 32107341, PMID 32126141, PMID 32705923, PMID 32770353, PMID 32785666, PMID 33028076, PMID 33035333, PMID 33243049, PMID 33334730, PMID 33448893, PMID 33586581, PMID 33683917, PMID 34296427, PMID 34310745, PMID 34493319, PMID 34515338, PMID 34691243, PMID 34749395, PMID 35086141
2014 (6), 2015 (4), 2016 (2), 2025 (2), P30CA138292 (2), 2005 (1), 2018 (1), 2023 (1), K12CA076930 (1), P30CA012197 (1), U01CA076576 (1), U10CA180820 (1)